SCHEMBL6113261

SCHEMBL6113261

Cc1ccc(C(=O)OC(=O)c2ccc(C)cc2C)c(C)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.49
MEN1 O00255 1/20 0.49
RAB9A P51151 3/20 0.47
NPC1 O15118 2/20 0.47
TNF P01375 1/20 0.47
PKM P14618 1/20 0.47
CDK5 Q00535 1/20 0.47
KLF5 Q13887 1/20 0.47
CDK5R1 Q15078 1/20 0.47
NOD1 Q9Y239 1/20 0.47
NFE2L2 Q16236 1/20 0.46
HTT P42858 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
TAS1R3 Q7RTX0 1/20 0.44
TAS1R1 Q7RTX1 1/20 0.44
TAS1R2 Q8TE23 1/20 0.44
HSD11B1 P28845 1/20 0.44
TDP1 Q9NUW8 2/20 0.43
MAPT P10636 1/20 0.43
TP53 P04637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29462647 1.00 KMT2A (0.49) KMT2AMEN1RAB9ANPC1TNF
SCHEMBL6113265 0.88 KMT2A (0.51) KMT2AMEN1RAB9ANPC1TNF
SCHEMBL15008746 0.88 NFE2L2 (0.45) KMT2AMEN1RAB9ANPC1TNF
SCHEMBL124710 0.87 KMT2A (0.49) KMT2AMEN1RAB9ANPC1TNF
SCHEMBL28488563 0.87 KMT2A (0.47) KMT2AMEN1RAB9ANPC1TNF
SCHEMBL30409908 0.85 NPC1 (0.47) KMT2AMEN1RAB9ANPC1TNF
SCHEMBL8527590 0.85 KMT2A (0.48) KMT2AMEN1RAB9ANPC1TNF
SCHEMBL158111 0.85 TDP1 (0.57) KMT2AMEN1HTTSMN1; SMN2TAS1R3
Tromethamine SCHEMBL21753739 0.85 KMT2A (0.43) KMT2AMEN1RAB9ANPC1TNF
SCHEMBL27440410 0.85 TPMT (0.48) KMT2AMEN1RAB9ANPC1TNF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110325601-B Liquid composition for inkjet and inkjet recording method 富士胶片株式会社 2022-03-15 CN disclosed
CN-109689805-B Liquid composition for inkjet and inkjet recording method 富士胶片株式会社 2021-12-21 CN disclosed
EP-2757102-B1 Intermediate for producing a cyclic sulfonic acid ester WAKO PURE CHEM IND LTD (JP) 2016-03-23 EP disclosed
US-8969591-B2 Method for producing cyclic sulfonic acid ester and intermediate thereof WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2015-03-03 US disclosed
EP-2463281-B1 METHOD FOR PRODUCING CYCLIC SULFONIC ACID ESTER AND INTERMEDIATE THEREOF WAKO PURE CHEM IND LTD (JP) 2014-10-22 EP disclosed
EP-2757102-A1 1,3-propanesultone derivative useful in the preparation of a 1,3-propenesultone derivative Wako Pure Chemical Industries, Ltd. (JP) 2014-07-23 EP disclosed
US-20140142324-A1 METHOD FOR PRODUCING CYCLIC SULFONIC ACID ESTER AND INTERMEDIATE THEREOF WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2014-05-22 US disclosed
US-8673963-B2 Method for producing cyclic sulfonic acid ester and intermediate thereof WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2014-03-18 US disclosed
EP-2463281-A1 METHOD FOR PRODUCING CYCLIC SULFONIC ACID ESTER AND INTERMEDIATE THEREOF Wako Pure Chemical Industries, Ltd. (JP) 2012-06-13 EP disclosed
US-20120130089-A1 METHOD FOR PRODUCING CYCLIC SULFONIC ACID ESTER AND INTERMEDIATE THEREOF WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2012-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140142324-A1 METHOD FOR PRODUCING CYCLIC SULFONIC ACID ESTER AND INTERMEDIATE THEREOF STS, TST, SULT1A1 KMT2A 2802/4885MEN1 3976/4885RAB9A 4715/4885
US-20120130089-A1 METHOD FOR PRODUCING CYCLIC SULFONIC ACID ESTER AND INTERMEDIATE THEREOF STS, TST, SULT1A1 KMT2A 2802/4885MEN1 3976/4885RAB9A 4715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.